National Enteric Surveillance Program (NESP)

ANNUAL SUMMARY 2014







TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH.

—Public Health Agency of Canada

Également disponible en français sous le titre : Programme national de surveillance des maladies entériques (PNSME) – rapport sommaire 2014

To obtain additional copies, please contact:

Public Health Agency of Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709

Fax: 613-941-5366 TTY: 1-800-465-7735

E-mail: publications@hc-sc.gc.ca

This publication can be made available in alternative formats upon request.

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2016

Publication date: June 2016

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. However, multiple copy reproduction of this publication in whole or in part for purposes of resale or redistribution requires the prior written permission from the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5 or copyright.droitdauteur@pwgsc.gc.ca.

Suggested Citation: Government of Canada. National Enteric Surveillance Program Annual Summary 2014: Public Health Agency of Canada, Guelph, 2016.

Cat.: HP37-15E-PDF ISBN: 2292-8561 Pub.: 160066

NATIONAL ENTERIC SURVEILLANCE PROGRAM (NESP)

ANNUAL SUMMARY 2014

INCLUDING SEROVAR AND PHAGE TYPE TABLES FOR 2014, NESP AND NML

The National Microbiology Laboratory (NML) and Centre for Foodborne, Environmental and Zoonotic Infectious Diseases (CFEZID), Public Health Agency of Canada

&

Provincial Public Health Laboratories

ACKNOWLEDGEMENTS

National Enteric Surveillance Program (NESP) Coordination Team:

Celine Nadon, Chief, Enteric Diseases Section, NML
Lori Lozinski, Clerk, Enteric Diseases Section, NML
Sara Christianson, Head, Reference Unit. Enteric Diseases Section, NML
Stephen Parker, Manager, Enteric Surveillance and Population Studies Division, CFEZID
Ashley Kerr, Epidemiologist, Enteric Surveillance and Population Studies Division, CFEZID
Pia K. Muchaal, Epidemiologist, Enteric Surveillance and Population Studies Division, CFEZID
Elizabeth Hillyer, Epidemiologist, Enteric Surveillance and Population Studies Division, CFEZID

Provincial/Territorial Laboratory Partners:

BC Centre for Disease Control Public Health Microbiology & Reference Laboratory
Alberta Provincial Microbiology Laboratory (ProvLab)
Saskatchewan Disease Control Laboratory
Cadham Provincial Microbiology Laboratory (Manitoba)
Public Health Ontario
Institut national de santé publique du Québec (INSPQ)
New Brunswick Public Health Laboratories
Nova Scotia Public Health Laboratories
Prince Edward Island Public Health Laboratories
Newfoundland and Labrador Public Health Laboratory

Provincial/Territorial Epidemiology Partners:

British Columbia Centre for Disease Control
Alberta Health
Saskatchewan Ministry of Health
Manitoba Health
Public Health Ontario
Ministère de la santé et des services sociaux du Québec
New Brunswick Health
Nova Scotia Department of Health and Wellness
Prince Edward Island Department of Health and Wellness
Newfoundland and Labrador Department of Health and Community Services
Yukon Health and Social Services
Northwest Territories Department Health and Social Services
Nunavut Health and Social Services

Executive Summary

The National Enteric Surveillance Program (NESP) is designed to detect and respond to multi-jurisdictional outbreaks and to integrate with national and international efforts to monitor and limit the spread of enteric diseases. This is achieved through weekly analysis and reporting of laboratory-confirmed isolations of enteric pathogens in Canada, including bacterial, viral and parasitic pathogens. Within Canada's multi-tiered surveillance systems for enteric diseases, NESP provides the first level of characterization – primarily species and serovar. These data are used as early warning signals, and are also critical to, and integrated with, downstream surveillance at the molecular and strain level (e.g., PulseNet Canada). This document is an annual summary of data submitted to NESP by provincial microbiology laboratories in 2014. For some pathogens reported to NESP, it is important to note that the isolates are only a subset of laboratory isolations within the province/territory and therefore may not reflect the incidence of disease reported through provincial and national notifiable disease surveillance systems.

In 2014, Salmonella continued to be the most common pathogen reported to NESP, with *S*. Enteritidis being the most common serovar. *S*. Enteritidis was reported nearly five times as often as any other serovar in 2014, and there was a 65% increase in the number of reported isolates of *S*. Enteritidis from 2013 to 2014. In contrast, *S*. Heidelberg rates have returned to baseline since a spike in 2012. The number of isolates of Vero-toxigenic (VTEC) *E. coli* O157 decreased between 2006 and 2010, with a slight increase into 2011, leaving the last three years to be relatively stable. Interestingly, the reporting of non-O157:H7 isolates to NESP is increasing with more specific subtyping information available. A total of 133 isolates of *Listeria monocytogenes* were reported to NESP in 2014. Lastly, after a subsequent drop in the number of reported isolates of *Shigella* spp. in 2013, reporting has slightly increased.

This report includes reference tables with a complete list of species and serovar data reported to NESP and phage types of isolates reported in 2014 at the National Microbiology Laboratory (NML).

This report also summarizes the extra-intestinal isolation sites and travel-associated infections reported through NESP. Although travel history is largely under-reported in NESP, 270 enteric infections (1.7% of all cases reported to NESP) were identified as associated with international travel. Similar to 2013, *Salmonella* infections were the most common, followed by parasites

4 | NATIONAL ENTERIC SURVEILLANCE PROGRAM (NESP) 2014

among travel-associated infections. Travel to the Caribbean (22%) and Asia (18%) were the most frequent destinations identified by travellers with travel-associated enteric infections.

TABLE OF CONTENTS

Executive Summary	3
Introduction	7
Isolates Reported By Major Organism Group	10
Salmonella	14
Salmonella Enteritidis, Salmonella Typhimurium and Salmonella Heidelberg	16
E. coli	20
Listeria monocytogenes	22
Shigella	23
Hepatitis A	24
Isolates Collected from Extra-intestinal Isolation Sites	24
Travel-Associated Infections	27
Summary	30
TABLES	
Table 1. Number of isolates reported to NESP by major organism group per province/territory, 2014	11
Table 2a. Annual national totals and rates (per 100,000) for major organism groups routinely reported to NESP, 2009-2014	12
Table 2b. Annual national totals and rates (per 100,000) for major organism groups under-reported to NESP, 2009-2014	12
Table 3. Rates (per 100,000) per province/territory for select major organism groups routinely reported to NESP, 2014	13
Table 4. Number of isolates reported to NESP per province and territory of the ten most commonly reported <i>Salmonella</i> serovars nationally, 2014	15
Table 5. National totals (overall rank) for the ten most commonly reported Salmonella serovars as reported to NESP, 2009-2014	15
Table 6. Serovar of <i>L. monocytogenes</i> isolates reported to the National Microbiology Laboratory by province, 2014	22
Table 7. Collection site of <i>L. monocytogenes</i> isolates as reported to NESP,	23
Table 8. Number of Hepatitis A isolates reported to NESP by Province and Territory, 2014	24
Table 9. Number of isolates collected from extra-intestinal sites as reported to NESP, 2014	25
Table 10. Number of infections by geographical region as reported to NESP,	27

Table 11. Number of travel-acquired infections reported to NESP by organism, 2014	28
Figures	
Figure 1. Relative national incidence rates of lab-confirmed cases of Salmonella, Shigella and E. coli O157 reported to NESP by year, 2010-2014	13
Figure 2. Proportion of Salmonella serovars as reported to NESP, 2014	14
Figure 3. Relative incidence rates of <i>S.</i> Enteritidis, <i>S.</i> Heidelberg, <i>S.</i> Typhimurium and other <i>Salmonella</i> serovars reported to NESP by Year, 2010-2014	17
Figure 4. Number of isolates reported to NML for the four most common phage types of S. Enteritidis and S. Typhimurium and the two most common phage types for S. Heidelberg, 2009-2014	18
Figure 5. Distribution of phage types reported to the NML for S. Enteritidis, S. Typhimurium and S. Heidelberg in 2014	19
Figure 6. Incidence rate of <i>E. coli</i> O157 VTEC and <i>E. coli</i> non-O157 serovars (including un-typed organisms) reported to NESP, 2005-2014	21
Figure 7. Incidence rate of <i>E. coli</i> non-O157 serovars and <i>E. coli</i> non-typed VTEC reported to NESP, 2005-2014	21
Appendices	
Appendix 1. Comparison of national totals, incidence per 100,000 and proportion captured between the Canadian Notifiable Disease Surveillance System (CNDSS) and NESP for enteric, food and waterborne diseases, 2013	31
Appendix 2. Species and serovar data reported to NESP by province and territory, 2014	32
Appendix 3. Phage types of isolates submitted to the NML, 2014	40
Appendix 4. Non-O157 serovars of verotoxigenic <i>E. coli</i> tested by the NML, 2014	53

Introduction

The National Enteric Surveillance Program (NESP) is designed to detect and respond to multi-jurisdictional outbreaks and to integrate with national and international efforts to monitor and limit the spread of enteric diseases. This is achieved through timely analysis and reporting for laboratory-confirmed isolations of enteric pathogens in Canada, including bacterial, viral and parasitic pathogens. In collaboration with related programs such as PulseNet Canada¹, NESP supports the real-time detection and response to emerging and priority diseases. Within Canada's multi-tiered surveillance systems for enteric diseases, NESP provides the first, and most timely, level of characterization, primarily species and serovar. These data are used as early warning signals, and are also critical to and integrated with downstream surveillance at the molecular and strain level (e.g., PulseNet Canada).

NESP is based on the collection of weekly aggregate laboratory data from across Canada, as submitted by the provincial public health microbiology laboratories to the National Microbiology Laboratory (NML) at the Public Health Agency of Canada (PHAC). Laboratories submit genus, species and serovar information on enteric microorganisms isolated from human patients. Data are submitted to NML either directly or using a web-based application (webNESP) hosted on the Canadian Network for Public Health Intelligence (CNPHI). Compilation and analysis weekly data is conducted jointly between NML and the Centre for Foodborne, Environmental and Zoonotic Infectious Diseases (CFEZID) and a weekly report is distributed. The report alerts provincial/territorial and federal partners to significant increases in the number of cases of enteric illness. To support communication of laboratory surveillance findings, webNESP allows partners to perform real-time data analysis, examine trends and display their data. PulseNet Canada uses these data in conjunction with laboratory DNA fingerprinting data determined by pulsed-field gel electrophoresis (PFGE) and other molecular or genomic data to detect disease clusters and outbreaks. The resulting data analyses are also shared on CNPHI between provincial public health microbiology laboratories, the Canadian Food Inspection Agency (CFIA), Health Canada (HC), PHAC and provincial/territorial epidemiologists. Notably, the coordinated assessment of laboratory evidence collected through these two complementary laboratory

¹ PulseNet Canada, National Microbiology Laboratory, Public Health Agency of Canada: https://www.nml-lnm.gc.ca/index-eng.htm

surveillance networks allows for the interpretation of clinical microbiological evidence during multi-jurisdictional epidemiologic investigations, as described in the Food-borne Illness Outbreak Response Protocol (FIORP)².

This annual report is a summary of the weekly data collected from all provincial public health microbiology laboratories, for the purpose of analyzing long-term trends in the incidence of enteric pathogens in Canada. For some organisms, the number of isolates reported to NESP is only a subset of laboratory isolations within the province and may not reflect the incidence of disease either provincially or nationally. However, within each disease group, the data may indicate changes in reported trends. Additional details are provided in the "Limitations" at the end of this section,

The Canadian Notifiable Diseases Surveillance System (CNDSS) receives data that are collected on a mandatory basis by local health units, forwarded to provincial/territorial health authorities and collated by the Surveillance and Epidemiology Division within the Centre for Communicable Diseases and Infection Control (CCDIC) at PHAC. These data may be more reliable indicators of total numbers of annual illnesses; however CNDSS is not designed to provide timely information required for cluster or outbreak detection. These two surveillance systems (CNDSS and NESP) are complementary in providing both epidemiological and laboratory results; however discrepancies between them do exist. A comparison of national case counts and incidence rates for enteric, food and waterborne diseases is included (Appendix 1).

Data Collection, Analysis and Dissemination:

Provincial public health laboratories receive isolates (or specimens) with accompanying submission forms. Laboratory personnel at each provincial laboratory perform appropriate tests to confirm the identification (and serovar, where appropriate) of the enteric pathogen. Weekly results from each provincial public health laboratory are summarized onto a NESP report form. The 'report week' for NESP spans each Sunday to Saturday and is based on the date the laboratory test was completed. The completed NESP report form is faxed or e-mailed to the NML as soon as possible and no later than the second day after a weekend or holiday. An exception to this reporting scheme occurs when the isolate must be sent to another laboratory

² Food-borne Illness Outbreak Response Protocol (FIORP) 2010: To guide a multi-jurisdictional response. Public Health Agency of Canada: http://www.phac-aspc.gc.ca/zoono/fiorp-pritioa/index-eng.php

for completion of the identification. In this case, the isolate is reported at the level of typing or identification attained (e.g. *Salmonella* sp.) for the week in which it was sent to the reference laboratory. The NESP record is then updated when the final identification is received from the reference laboratory (e.g. report in week 35 that one *Salmonella* sp. reported in week 33 has been confirmed as *S.* Anatum). This updated information is submitted with the next weekly NESP report form.

All data sent to NESP are aggregate (i.e., the total number of each organism in the province) and do not contain any patient identifiers, locators, or other private information. NESP partners endeavor to include only the number of isolates from new cases identified at the laboratory that week, or updates to previously reported numbers. To avoid duplication, the provincial laboratories attempt to identify multiple, repeat, or follow-up specimens from the same individual, and consider all identical isolates from the same patient that are collected over a 3-month period as a single case.

With respect to data analysis, NESP uses an algorithm to determine whether case counts are significantly higher than the expected baseline. The cumulative Poisson probability between the reported case count and the retrospective 5-year median value is used to determine statistical significance.

The NESP Weekly Report is sent to all provincial laboratories, at least one epidemiologist or Medical Officer of Health in each province/territory, and multiple stakeholders at the federal level. The reports may be shared with other public health professionals who have an operational need to have this information, but are not for public distribution. There is no required response by public health professionals to the events or statistical elevations noted in the reports. These reports aim to provide useful and timely information for those responsible for public health action and they have been used by PHAC, in collaboration with public health partners in provinces, to trigger further public health investigation of potential outbreaks or to inform the activities of downstream surveillance systems such as PulseNet Canada.

Limitations:

It should be noted that there are some inherent limitations of these data. Not all specimens/isolates are referred from the regional and local laboratories to the provincial public health laboratories and therefore the provincial reports and NESP data may be an under-

representation of the true incidence of disease in Canada. For example, Campylobacter isolates are not routinely forwarded to provincial or central reference laboratories for further testing beyond genus/species characterizations and are therefore greatly under-represented in NESP. However, Salmonella and Escherichia coli O157 isolates captured by NESP are more representative of the true incidence of disease in Canada, as the number of cases reported to CNDSS and isolates reported to NESP show a high degree of concurrence for both diseases. In some cases, there may be over-reporting of organisms in NESP due to reporting of multiple specimens from a single patient, but efforts are made to minimize this occurrence. Information regarding extra-intestinal isolation sites, foreign travel, and outbreaks and case clusters are not routinely or consistently reported to NESP from all laboratories and therefore any interpretation should be considered with caution. Outbreaks and clusters reported to NESP do not represent all enteric illness outbreaks identified nationally, and case counts reported to NESP may not be representative of the actual final number of cases associated with outbreaks and clusters. Therefore, details regarding outbreaks and case clusters are not included in this report; these are more accurately tracked within PulseNet Canada or through other systems, including the Outbreak Summaries Surveillance system.

Isolates Reported By Major Organism Group

A total of 16,151 enteric pathogens were reported to NESP in 2014. The number of cases reported per province and territory for each major organism group is shown in Table 1. For bacterial pathogens, the isolates were grouped by genus, whereas parasites and viruses were each grouped respectively. A complete list of all organisms reported to NESP by province and territory in 2014 is shown in Appendix 2.

The most frequently reported enteric pathogen in 2014 was *Salmonella*, followed by enteric viruses (Norovirus, Hepatitis A, Rotavirus and Adenovirus) and enteric parasites (*Giardia*, *Cryptosporidium*, *Entamoeba histolytica/dispar* and *Cyclospora*) (Table 1). As mentioned previously, this does not reflect national incidence rates but rather testing and reporting practices within the provincial laboratories.

Table 1. Number of isolates reported to NESP by major organism group per province/territory, 2014

GROUP	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT	NT	NU	TOTAL	% OF TOTAL ISOLATES REPORTED
Campylobacter ¹	436	273	138	93	161	197	200	99	42	37				1676	10.4
E. coli ²	124	206	36	40	123	84	3	9	10	8				643	4.0
Listeria	18	10	2	3	45	46	3	4	1	1				133	0.8
Salmonella	1231	1008	184	250	3207	1443	185	213	34	89		3	4	7851	48.6
Shigella	136	88	15	32	275	120	4	7	3	1				681	4.2
Vibrio	39	19	1		4	12	2	3	1		1			82	0.5
Yersinia	78	47	25		124	59	4	1		2	1			341	2.1
Parasites ¹	214	6	121	204	631	360	102	114	15	24	20			1811	11.2
Viruses ¹	393	271	188	119	912	534	171	149	85	110		1		2933	18.2
Total	2669	1928	710	741	5482	2855	674	599	191	272	22	4	4	16151	100

¹ Campylobacter, parasitic (Giardia, Cryptosporidium, Entamoeba histolytica/dispar and Cyclospora), and viral (Norovirus, Rotavirus and Adenovirus) infections are not routinely reported to the provincial or central reference laboratories and are greatly under-represented in NESP.

National incidence rates of the major organism groups over the last six years are shown in Tables 2a and 2b. Rates (per 100,000) are based on the number of isolates reported to NESP each year. Isolates of organisms such as *E. coli* O157, *Listeria monocytogenes*, *Salmonella* and *Shigella* are routinely forwarded to provincial microbiology laboratories and as such, NESP incidence rates are considered to be reflective of true incidence rates for these pathogens. The provincial and territorial incidence rates for the organisms that are routinely reported to NESP are shown in Table 3. Five-year trends (2010-2014) in the national incidence rate for *Salmonella*, *Shigella* and *E. coli* O157 compared to the previous 5-year baseline (2005-2009) are shown in Figure 1. Since *Listeria monocytogenes* was added to NESP in July 2010, there is currently not enough data to provide this type of trend analysis.

Campylobacter, enteric parasites (Giardia, Cryptosporidium, Entamoeba histolytica/dispar and Cyclospora) and enteric viruses (Norovirus, Rotavirus and Adenovirus), as previously mentioned, are not routinely reported to the provincial or central reference laboratories (Table 2b

² E. coli includes O157 serovars (458 cases), non-O157 serovars (151 cases), and non-typed VTEC (34 cases).

and Appendix 1). Therefore, NESP incidence rates are not presented for these pathogens as they are difficult to interpret and changes may not reflect actual changes in disease rates.

Table 2a. Annual national totals and rates (per 100,000) for major organism groups routinely reported to NESP, 2009-2014¹

Group	20	009	2010		20)11	20)12	20)13	2014		
	Total	Rate											
E. coli O157 ²	529	1.57	405	1.19	481	1.40	486	1.39	470	1.33	458	1.28	
Listeria ³					132	0.38	124	0.36	117	0.33	133	0.37	
Salmonella	6084	18.02	7254	21.25	6806	19.74	6980	20.01	6270	17.77	7851	22.00	
Shigella	631	1.87	739	2.17	861	2.50	988	2.83	621	1.76	681	1.91	

¹Rates calculated using the population estimates for Canada as of October 1 for years 2009 to 2014 as reported by Statistics Canada.

Table 2b. Annual national totals and rates (per 100,000) for major organism groups under-reported to NESP, 2009-2014¹

Group	20	09	2010		20)11	2012		2013		2014	
	Total	Rate	Total	Rate	Total	Rate	Total	Rate	Total	Rate	Total	Rate
Campylobacter	1751	5.19	1837	5.38	1938	5.62	1994	5.72	1866	5.29	1676	4.70
Vibrio	47	0.14	51	0.15	47	0.14	61	0.17	48	0.14	82	0.23
Yersinia	382	1.13	341	1.00	381	1.11	322	0.92	278	0.79	341	0.96
Parasites	1570	4.65	1585	4.64	1190	3.45	1320	3.78	1665	4.72	1811	5.08
Viruses	3184	9.43	4662	13.66	4441	12.88	4523	12.97	4058	11.50	2933	8.22

¹Rates calculated using the population estimates for Canada as of October 1 for years 2009 to 2014 as reported by Statistics Canada.

²Only cases of *E. coli* O157 are included in this table; additional details about *E. coli* non-O157 are outlined in the *E. coli* section of this report.


³Reporting of *Listeria monocytogenes* to NESP began in July 2010.

Table 3. Rates (per 100,000) per province/territory for select major organism groups routinely reported to NESP, 2014¹

GROUP	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT	NT	NU
E. coli O157 ²	1.18	4.49	0.36	1.71	0.84	0.64	0.40	0.95	6.14	0.19			
Listeria	0.39	0.24	0.18	0.23	0.33	0.56	0.40	0.42	0.68	0.19			
Salmonella	26.39	24.31	16.33	19.46	23.36	17.52	24.50	22.57	23.21	16.83		6.80	11.03
Shigella	2.92	2.12	1.33	2.49	2.00	1.46	0.53	0.74	2.05	0.19			

¹Rates calculated using preliminary post-censal population estimates for the provinces and territories as of October 1, 2015 from Statistics Canada.

Figure 1. Relative national incidence rates¹ of lab-confirmed cases of *Salmonella*, *Shigella* and *E. coli* O157 reported to NESP by year, 2010-2014



¹Rates are compared to the 2005-2009 5-year baseline period.

²Only cases of *E. coli* O157 are included in this table, as *E. coli* non-O157 is not consistently reported by provinces and territories.

Salmonella

A total of 7,851 *Salmonella* isolates and 244 different serovars were reported to NESP in 2014. The 10 most commonly reported *Salmonella* serovars accounted for 77% of the total *Salmonella* infections reported (Figure 2). The total numbers of isolates identified in each province and territory of the 10 most commonly reported *Salmonella* serovars nationally are listed in Table 4, while a full list of the number of *Salmonella* serovars reported to NESP by each province and territory in 2014 is presented in Appendix 2.




Figure 2. Proportion of Salmonella serovars as reported to NESP, 2014 (n=7,851)

S. Enteritidis, S. Typhimurium, and S. Heidelberg remain the top three most commonly reported Salmonella serovars in NESP. This observation has been unchanged since the beginning of NESP; however, the ranking between the top three has shifted from year to year. In 2012 it was noted that for the first time in eight years there were more reports of S. Heidelberg than S. Typhimurium. In comparison, S. Typhimurium has moved back to being the second most commonly reported in 2014 behind S. Enteritidis. The provincial distribution of the ten most commonly reported Salmonella serovars in 2014 is highlighted in Table 4. The ten most

¹ Other serovars (1,780 isolates) were divided among 233 serovars and 10 isolates were reported as unspecified *Salmonella* species.

commonly reported *Salmonella* serovars in 2014 are compared to the top ten reported serovars in the previous five years in Table 5. As a comparison, the serovars that have dropped in ranking but have previously been identified in the top 10 within the past five years are included at the bottom of the table.

Table 4. Number of isolates reported to NESP per province and territory of the ten most commonly reported *Salmonella* serovars nationally, 2014

Serovar	вс	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT	NT	NU	TOTAL	% of Salmonella Total
Enteritidis	629	494	84	99	1225	507	100	128	21	48		1	1	3337	43
Typhimurium	77	94	15	19	307	134	10	8	3	3			1	671	9
Heidelberg	32	38	9	13	289	195	20	18	-	13			1	628	8
Thompson	10	10		3	210	124	12	13	1	9				392	5
ssp I 4,[5],12:i:-	36	48	16	3	96	43	7	2						251	3
Newport	34	11	6	7	89	60	9	6	1	1				224	3
Infantis	25	12	1	11	74	35	2	1	1	2				164	2
Typhi	31	20	2	1	77	8		1						140	2
Javiana	24	16	4	7	56	19	2	3	2					133	2
Saintpaul	28	28		5	40	25	1	2	1	1				131	2
Top Ten Total	926	771	137	168	2463	1150	163	182	30	77	0	1	3	6071	77

Table 5. National total counts (overall rank) for the ten most commonly reported *Salmonella* serovars as reported to NESP, 2009-2014

Serovar	2009	2010	2011	2012	2013	2014
Enteritidis	1955 (1)	2828 (1)	2763 (1)	2117 (1)	2019 (1)	3337 (1)
Typhimurium	777 (2)	827 (2)	661 (2)	814 (3)	668 (3)	671 (2)
Heidelberg	665 (3)	787 (3)	641 (3)	1071 (2)	733 (2)	628 (3)
Thompson	99	107 (7)	118 (8)	265 (5)	149 (6)	392 (4)
ssp I 4,[5],12:i:-	271 (4)	278 (4)	218 (4)	281 (4)	299 (4)	251 (5)
Newport	133 (6)	146 (6)	195 (6)	153 (7)	189 (5)	224 (6)
Infantis	110 (8)	106 (8)	185 (7)	184 (6)	116 (8)	164 (7)
Typhi	164 (5)	180 (5)	196 (5)	144 (8)	134 (7)	140 (8)
Javiana	102 (9)	90	77	87	113 (9)	133 (9)
Saintpaul	130 (7)	88	101 (9)	94	91 (10)	131 (10)
Hadar	100 (10)	95 (10)	75	70	73	61
Paratyphi A	92	91	94 (10)	79	73	64
Oranienburg	53	104 (9)	52	55	64	81
ssp I 4,[5],12:b:-	75	90	62	108 (9)	59	40
Braenderup	69	73	78	98 (10)	57	71

The reporting of *S*. Thompson infections during 2014 achieved its highest ranking in comparison to previous years. This is primarily due to a large multi-provincial outbreak of *S*. Thompson (highly concentrated in a single province), which was initially triggered by weekly NESP data. Several multi-provincial increases in specific *Salmonella* serovars were also noted in NESP in 2014. These increases were flagged in 23 NESP Weekly Reports as the "Topic of the Week" highlighting various *Salmonella* serovars (Typhimurium, Schwarzengrund, Enteritidis, Newport, Thompson, Litchfield, Bovismorbificans, Virchow, ssp I 4,[5],12:i:-, Infantis, Muenchen, and Javiana).

Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Heidelberg

In 2014, 3,337 isolates of *S.* Enteritidis were reported to NESP and reflects approximately 43% of all *Salmonella* isolates reported. Increased counts were noted in 2010, 2011 and again in 2014. (Table 5; Figure 3). After an observed increase in the number of *S.* Heidelberg infections reported in 2012 (above the baseline period (2005-2009), there was a subsequent decrease (and return to baseline) in cases reported to NESP in 2014. There has been a decline in the incidence of *S.* Typhimurium, while the incidence rate of all other *Salmonella* serovars combined from 2013 to 2014 compared to the 2005-2009 baseline period remained relatively unchanged (Figure 3).




Figure 3. Relative incidence rates¹ of *S.* Enteritidis, *S.* Heidelberg, *S.* Typhimurium and other *Salmonella* serovars reported to NESP by Year, 2010-2014


¹ Rates are compared to the 2005-2009 baseline period.

For most other serovars of *Salmonella*, PFGE is relied upon to differentiate among isolates and to identify case clusters, which is done through PulseNet Canada. For *S.* Enteritidis and *S.* Heidelberg, however, PFGE does not provide optimal discrimination. For these serovars, phage typing is useful for detecting trends and potential case clusters. When used in conjunction with PulseNet Canada molecular data, phage types can facilitate cluster detection and outbreak response, but on their own they also provide insight into overall trends among these frequently occurring serovars.

The numbers of reported isolates for the most common phage types reported by the NML in 2014 are shown in Figure 4 compared to the number of isolates of that phage type reported in the past five years. In 2014 there was an increase in the top four most commonly reported *S*. Enteritidis phage types: 8, 13, 13a, and 64. Phage type 64 has been continuing to increase since 2011, whereas after being stable from 2012 to 2013, phage types 13 and 13a have begun to increase once again. A steep increase in phage type 8 has occurred. Of the top four *S*. Typhimurium phage types, phage type 10 has been slowly increasing up until 2014 where a slight decrease in reported isolates has been observed. After a high level of reporting in 2009, *S*. Typhimurium phage type 108 sharply diminished in 2010 with a spike occurring again in 2012 to a more recent decline in 2014. *S*. Heidelberg phage type 19 is still on the decline after a major increase in reporting observed in 2012. The top four *S*. Enteritidis, top four *S*. Typhimurium and top two *S*. Heidelberg phage types account for 71%, 37%, and 59% of the all

phage types reported for each serovar by the NML in 2014, respectively (Figure 5). All Salmonella phage types reported by the NML in 2014 are listed in Appendix 3. It is important to note that phage types are not analyzed in NESP on a weekly basis, as PulseNet Canada utilizes molecular methods to differentiate subtypes in real-time. Phage type data have been used to identify long-term trends, to inform PulseNet Canada surveillance and outbreak response activities, and for provincial-level activities. It is expected that phage typing will eventually be phased out in the near- to mid-term as molecular and genomic methods are implemented.

Figure 4. Number of isolates reported to NML for the four most common phage types of a) *S.* Enteritidis and b) *S.* Typhimurium and the two most common phage types for c) *S.* Heidelberg, 2009-2014








Figure 5. Distribution of phage types reported to the NML for *S.* Enteritidis, *S.* Typhimurium and *S.* Heidelberg in 2014





^{*}PT64 was previously known as ATEN-16

Escherichia coli

NESP observed a significant decline in reported cases of verotoxigenic *E. coli* (VTEC) O157 between 2006 and 2010 (Figure 6). With a slight increase from 2010 to 2011, the overall incidence rates for the following years remained relatively consistent (1.40 cases per 100,000 in 2011, 1.39 cases per 100,000 in 2012, 1.33 cases per 100,000 in 2013, and 1.28 cases per 100,000 in 2014).

The national incidence rate of *E. coli* non-O157 reported to NESP increased from 0.12 cases/100,000 in 2008 to 0.52 cases/100,000 in 2014 (Figure 6). It should be noted that *E. coli* non-O157 are reported less consistently than *E. coli* O157 to NESP by the provincial laboratories (as many are not identified or sent to provincial laboratories) and that the specific serovar of an *E. coli* non-O157 isolate is not always reported or available. Incidence rate trends of *E. coli* non-O157 serovars and *E.coli* non-typed VTEC are illustrated in Figure 7. An increasing trend of reporting specific serovar information for *E. coli* non-O157 isolates to NESP has been noted, likely as result of increased recognition of the importance of non-O157 VTEC in food safety and therefore a response in testing practices by some provincial laboratories. In 2014 there were 129 isolates reported, compared to 85 in 2013, and 43 in 2012. The top three most commonly reported non-O157 serovars to NESP are: *E. coli* O26:H11 (24 isolates), *E. coli* O111:H Nonmotile (20 isolates), and *E. coli* O121:H19 (15 isolates). All *E. coli* serovar data reported to NESP is listed in Appendix 2. Serovar information is also available for the confirmed non-O157 VTEC isolates sent to the NML in 2014 (Appendix 4).

Figure 6. Incidence rate of *E. coli* O157 VTEC and *E. coli* non-O157 serovars (including un-typed organisms) reported to NESP, 2005-2014





Figure 7. Incidence rate of *E. coli* non-O157 serovars and *E. coli* non-typed VTEC reported to NESP, 2005-2014



E. coli non-O157 (sub-typed) refers to isolates where a specific serovar was reported.

E. coli non-O157 (not sub-typed) refers to isolates that were reported as *E. coli* non-O157 but no specific serovar was reported.

E. coli non-typed VTEC refers to any non-typed E. coli (could be O157 or non-O157).

Listeria monocytogenes

In July 2010, the list of organisms included in NESP was expanded to include L. monocytogenes. This addition was designed to provide increased national surveillance of invasive listeriosis. A total of 133 isolates were reported in 2014 with a median of three isolates reported nationally per week, and the provincial and territorial distribution of these isolates is highlighted in Table 1. The incidence rate of L. monocytogenes from 2011 to 2013 has dropped slightly from 0.38 to 0.33 cases per 100,000, respectively. However, from 2013 to 2014 the incidence rates returned to 0.37 cases per 100,000. The results of serotyping performed by the NML in 2014 are outlined in Table 6 (note: this will be the last year the NESP report includes L. monocytogenes serovars – as this test was discontinued in 2015).

Table 6. Serovar of *L. monocytogenes* isolates reported to the National Microbiology Laboratory by province, 2014¹

Serovar	ВС	AB	SK	MB	ON	QC^2	NB	PE	NS	NL	Total
1/2a	6	5	-	1	10	-	-	-	2	1	25
1/2b	-	-	-	-	5	-	-	-	-	-	5
4a	-	-	-	-	2	-	-	-	-	-	2
4b	1	5	1	2	30	-	3	2	2	1	47
4d	-	-	1	-	1	-	-	-	-	-	2
Total L. monocytogenes	7	10	2	3	48	-	3	2	4	2	81

¹This data includes only isolates collected from extra-intestinal collections site and excludes 'unknown' collection sites. Isolates from animals, food and the environment are excluded as well as multiple isolates collected from the same case.

According to the case definition for invasive listeriosis, only isolates obtained from a normally sterile site or placental/fetal tissues should be reported to NESP. Therefore, unlike the other enteric organisms included in NESP, all *L. monocytogenes* isolates are from extra-intestinal sites. The isolation sites of *L. monocytogenes* reported to NESP are shown in Table 7; blood and cerebrospinal fluid are still the most common sites reported.

² Quebec does not submit *L. monocytogenes* isolates for serotype testing to NML

Table 7. Collection site of L. monocytogenes isolates as reported to NESP, 2014


Site	No. Isolates	Percent (%)
Blood	108	81.2%
Cerebrospinal fluid	17	12.8%
Other tissue or fluid ¹	8	6.0%
Total	133	-

¹Joint fluid (2), placenta, abdominal fluid, intra-cranial fluid, urine, amniotic fluid, gall bladder

Shigella

In 2014, 681 *Shigella* isolates were reported to NESP, with approximately half being *Shigella sonnei* (n=375). After a sharp decline in cases reported between 2012 and 2013, there was a slight increase in the overall reporting of *Shigella* infections in 2014 (1.75 cases per 100,000 in 2013 to 1.91 cases per 100,000 in 2014).

Figure 8. Incidence rate of Shigella species reported to NESP, 2005-2014



Hepatitis A

In July 2012, the list of organisms included in NESP was expanded to include Hepatitis A. This addition was designed to provide timely national surveillance of Hepatitis A for multi-jurisdictional outbreak detection. The data in this report represents the second complete year of data collection on Hepatitis A, and the number of isolates reported by each province/territory is highlighted in Table 8 and Appendix 2. There were 208 cases (incidence rate of 0.58 cases per 100,000 population) reported to NESP in 2014.

It is important to note that there are multiple streams for reporting Hepatitis A cases to NESP. In provinces where Hepatitis A testing is done primarily by private or hospital laboratories, a weekly count of the number of cases is provided by the provincial/territorial ministry of health. In other provinces where testing is conducted at the provincial laboratory, the cases are routinely reported to NESP similar to the other organisms under surveillance. The timeliness of reporting will depend, in part, on whether the data is reported via the provincial laboratory or epidemiology arm of public health.

Table 8. Number of Hepatitis A isolates reported to NESP by Province and Territory, 2014

	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT	NT	NU	TOTAL
Hepatitis A	21	27	17	8	83	46	-	3	-	3	-	-	-	208

Isolates Collected from Extra-intestinal Isolation Sites

Isolation of an organism from a sterile site may reflect more severe illness and an increased likelihood to seek treatment and submit a specimen for testing. The number of isolates collected from extra-intestinal sites (excluding *L. monocytogenes*) reported to NESP in 2014 is outlined in Table 9. Although information regarding extra-intestinal isolation sites is collected by NESP, these data are not consistently reported to provincial laboratories and therefore may not be adequately represented in the NESP report.

Table 9. Number of isolates collected from extra-intestinal sites as reported to NESP, 2014

Organism	Blood	Urine	Other ¹	Total/Overall	Percent (%)
Campylobacter	38	0	2	40/1676	2.4
fetus ssp fetus	15		1	16/44	36.4
jejuni	20			20/1214	1.6
Other species ²	3		1		
E. coli		1		1/643	0.2
E. coli O157:H7		1		1/400	0.3
Salmonella serovar	333	204	40	577/7851	7.3
Agona	2	3	1	6/78	7.7
Anatum	1	2		3/27	11.1
Bovismorbificans	1		2	3/34	8.8
Braenderup		3		3/71	4.2
Brandenburg	3	1	1	5/24	20.8
Chester	2	1		3/19	15.8
Derby	1	2		3/28	10.7
Dublin	6	1		7/19	36.8
Eastbourne	2			2/21	9.5
Ebrie	1		1	2/5	40.0
Enteritidis	100	49	15	164/3337	4.9
Hadar	1	5		6/61	9.8
Hartford	1	3		4/45	8.9
Heidelberg	42	21	5	68/628	10.8
Infantis	1	4	1	6/164	3.7
Javiana	5	7		12/133	9.0
Kentucky	1	2		3/30	10.0
Litchfield		2		2/27	7.4
Mbandaka		1	1	2/25	8.0
Montevideo	2	4		6/31	19.4
Muenchen	1	8		9/81	11.1
Newport	5	8		13/224	5.8
Ohio	1	1		2/5	40.0
Oranienburg	7	8	1	16/81	19.8
Panama	4	1		5/31	16.1
Paratyphi A	31	1		32/64	50.0
Poona	2			2/21	9.5
Reading	2			2/19	10.5
Saintpaul	6	3	1	10/131	7.6
Schwarzengrund	7	3		10/59	16.9
Senftenberg		8		8/35	22.9

Organism	Blood	Urine	Other ¹	Total/Overall	Percent (%)
Tennessee		1	1	2/10	20.0
Thompson	10	5	1	16/392	4.1
Typhi	51			51/140	36.4
Typhimurium	13	11	4	28/671	4.2
Virchow	5		1	6/26	23.1
ssp I	1	1		2/13	15.4
ssp I 4,[5],12:i:-	3	3		6/251	2.4
ssp I 6,7,[14]:c:-			2	2/2	100.0
ssp I 9,12:-:-	1	1		2/5	40.0
ssp I Rough-O:-:-		5		5/11	45.5
Other serovars ³	11	25	2		
Shigella species	3		1	4/681	0.6
flexneri 3			1	1/15	6.7
flexneri 3b	1			1/23	4.3
flexneri	1			1/18	5.6
sonnei	1			1/375	0.3
Vibrio species			4	4/82	4.9
alginolyticus			2	2/6	33.3
cholerae			1	1/1	100.0
parahaemolyticus			1	1/50	2.0
Yersinia species	1		2	3/341	0.9
enterocolitica	1		2	3/302	1.0
Total	375	204	49	629	

¹ Other sites include: **Abscess:** *S.* Enteritidis (1), *S.* Mbandaka (1), *S.* Virchow (1); **Abdominal fluid:** *S.* Heidelberg (1), *S.* Enteritidis (1), *S.* Agona (1), *C. curvus* (1); **Abdominal pus:** *S.* Enteritidis (1); **Aorta:** *S.* ssp | 6,7,[14]:c:- (1); **Biliary fluid:** *S.* Thompson (1); **Biopsy – unknown:** *S.* Enteritidis (1), *S.* Newport (1); **Biopsy – lung:** *S.* Enteritidis (1); **Biopsy – terminal ileum:** *S.* Sandiego (1); **Bronchoalveolar lavage:** *S.* Typhimurium (1); **Colon biopsy:** *S.* Brandenburg (1); **Elbow:** *S.* Ebrie (1); **Foot:** *V. alginolyticus* (1); **Hip puncture:** *C. fetus* ssp *fetus* (1); **Hip swab:** *S.* Oranienburg (1); **Joint fluid:** *S.* Enteritidis (1); **Left vertebral fluid:** *S.* Heidelberg (1); **Leg:** *S.* Saintpaul (1), *S.* ssp | 6,7,[14]:c:- (1); **Lung cavity fluid:** *S.* Enteritidis (1), **Pancreatic pseudocyst:** *S.* Enteritidis (1), **Peri-anal abscess:** *S.* Enteritidis (1); **Pleural fluid:** *S.* Enteritidis (1), *S.* Typhimurium (1); **Scrotum:** *S.* Enteritidis (1), **Serum:** *S.* Infantis (1), **Sputum:** *S.* Heidelberg (1); **Tissue - unknown:** *S.* Enteritidis (1), *S.* Heidelberg (1); **Tissue - micotic aortic aneurysm:** *S.* Enteritidis (1); **Toe:** *V. cholerae*; **Wound:** *S.* Bovismorbificans (2), *S.* Enteritidis (2), *S.* Heidelberg (1), *S.* Typhimurium (2), *S.* ssp | O-:l,z13,l,z28:e,n,z15 (1), *V.* alginolyticus (1), *V. parahaemolyticus* (1), *Y. enterocolitica* (2).

Travel-Associated Infections

Although foreign travel is an important risk factor for gastro-intestinal illness, this information is rarely reported to provincial laboratories and is therefore greatly under-represented in NESP. A total of 270 cases of enteric infection recorded through NESP were reported in foreign travelers or new immigrants arriving in Canada (Table 10 & Table 11). This represents only 1.7% of all pathogens reported to NESP in 2014. The Caribbean and Asia were the most frequently identified regions and were associated with 22% (60 cases) and 18% (48 cases) of travel-acquired infections, respectively. The Caribbean and Central America are popular winter destinations for Canadians and represent 38% of the travel-acquired infections reported.

Table 10. Number of infections by geographical region as reported to NESP, 2014

Geographic Region	No. of Cases (%)
Caribbean	60 (22.3)
Asia	48 (17.8)
Central America	42 (15.6)
Africa	38 (14.1)
South America	12 (4.5)
North America	8 (3.0)
Europe	5 (1.9)
Oceania	4 (1.5)
Multiple regions	12 (4.5)
Destination not identified	41 (15.2)
Total	270

² Other species of *Campylobacter* include those where only a single isolate from an extraintestinal source was reported: *C. curvus*, *C. jejuni/coli*, *C. lari*, and *C.* sp.

³ Other *Salmonella* serovars include those where only a single isolate from an extra-intestinal source was reported: *S.* Alachua, *S.* Amsterdam, *S.* Apapa, *S.* Arechavaleta, *S.* Bonariensis, *S.* Bradford, *S.* Bredeney, *S.* Chailey, *S.* Cotham, *S.* Give, *S.* Haifa, *S.* Kiambu, *S.* Livingstone, *S.* Meleagridis, *S.* Michigan, *S.* Muenster, *S.* Orientalis, *S.* Paratyphi B var. Java, *S.* Rissen, *S.* Sandiego, *S.* Stanley, *S.* Telelkebir, *S.* Uganda, *S.* Urbana, *S.* Weltevreden, *S.* ssp I (multiple), and *S.* ssp IIIb (multiple).

Salmonellosis was the most commonly reported travel-related infection, accounting for 35% of travel associated cases reported to NESP in 2014. Parasitic infections were also frequently reported (29% of travel cases), specifically Giardiasis, which alone accounted for 19% of all travel associated infections. Information on countries of travel was not available for 15% of travel-associated infections

There were two cases of *Vibrio cholerae* O1 reported to NESP in 2014, one with travel to India and the other with travel to Cuba during their exposure period.

Table 11. Number of travel-acquired infections reported to NESP by organism, 2014

Organism	No. of Cases (% of total travel)	% of Pathogen Total	Country or Region (number of cases >1) ¹
Campylobacter species	38 (14.1%)	2.3	
coli	3	1.8	Mexico, Multiple destinations (2) (India, Nepal, Bangladesh)
jejuni	11	0.9	Africa, Dominican Republic, Fiji, Greece, Mexico (2), Multiple destinations (2) (Mexico, Dominican Republic, Asia), Nepal, Pakistan, Tahiti
jejuni/coli	24	24.0	Africa, China, Cuba (2), Dominican Republic (2), Italy, Jamaica, Japan, Kenya, Mexico, Peru (2), Tanzania, Turkey, Unknown (7), USA
Salmonella enterica subsp. enterica serovars	93 (34.6%)	1.2	
Enteritidis	44	1.3	Cuba (21), Dominican Republic (5), India, Mexico (14), Multiple destinations (3) (Cuba, Mexico, China)
Javiana	3	2.3	Cuba (3)
Mbandaka	2	8.0	Dominican Republic (2)
Newport	3	1.3	Cuba, Mexico (2)
Paratyphi A	2	3.1	India, Pakistan
Saintpaul	3	2.3	Brazil, USA, Jamaica
ssp I 4,[5],12:i:-	3	1.2	Lebanon (2), Mexico
Typhi	9	6.4	India (8), Pakistan (1)
Typhimurium	6	0.9	Mexico (3), Multiple destinations (Mexico, Cuba)
Other serovars ²	18		Cuba (5), Ecuador, Europe, Jamaica, Lebanon, Mexico (4), Multiple destinations (Cambodia and Vietnam), Pakistan, Philippines (3)

Organism	No. of Cases (% of total travel)	% of Pathogen Total	Country or Region (number of cases >1) ¹
Shigella species	17 (6.3%)	2.5	
dysenteriae 2	2	40.0	Dominican Republic (2)
flexneri ³	6	4.1	India (2), Multiple destinations (2) (Vietnam, Cambodia, Laos, Mexico, India, Chile, Bolivia, Peru, and Colombia), Saudi Arabia, Somalia
sonnei	9	2.4	Cuba, Dominican Republic, India, Mexico (3), Thailand, USA
Vibrio species	2 (0.7%)	2.4	
cholerae O1	1	100.0	India
cholerae O1 Ogawa	1	100.0	Cuba
Yersinia species	3 (1.1%)	0.9	
enterocolitica	2	0.7	Cuba (2)
intermedia	1	7.1	Mexico
Parasites	77 (28.6%)	4.3	
Cryptosporidium	3	0.7	Cuba, Dominican Republic, Unknown
Cyclospora	1	3.6	Mexico
Entamoeba histolytica/dispar	23	4.2	Africa (2), Colombia (2), Congo (2), Cuba, Ecuador (2), Eritrea, India, Iran, Mozambique, Spain, Uganda, Unknown (8)
Giardia	50	6.1	Africa, Bhutan, Colombia, Congo (3), Costa Rica, Iraq, Jamaica, Kenya (3), Middle east, Morocco, Nepal, New Zealand, Republic of Cameroon (2), Rwanda (4), Somalia, Sudan, Tanzania, Unknown (23)
Viruses	40 (14.9%)	1.4	
Hepatitis A	39	18.8	Africa (2), Algeria, Bangladesh, Chad, China, Cuba, Dominican Republic, El Salvador, Ethiopia (2), Europe, Fiji, Guatemala, Haiti, Honduras, India (4), Mexico (4), Morocco (2), Multiple destinations (Singapore, Istanbul, Philippines, and Dubai), Nicaragua, Pakistan (3), Peru (1), Philippines (2), Tanzania, Unknown, USA (3)
Rotavirus	1	0.2	Cuba
Total	270	1.7	

¹ Where more than one case reported travel to a country or region, the number of travelers is indicated in brackets.

² Other serovars includes the *Salmonella* serovars that were reported as travel-associated by a single case including: *S.* Anatum, *S.* Berta, *S.* Blockley, *S.* Bredeney, *S.* Concord, *S.* Derby, *S.*

Hadar, S. Havana, S. Javiana, S. Newport, S. Oranienburg, S. Paratyphi B var. Java, S. Singapore, S. ssp I Rough-O:e,h:1,5, S. Uganda and S. Virchow.

³ S. flexneri category includes S. flexneri 6, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a.

Summary

Since its inception in 1997, NESP has developed a robust database of information pertaining to laboratory-confirmed isolations of enteric pathogens in Canada. With the ongoing collaboration of federal, provincial and territorial laboratory and epidemiological partners, NESP is used for its ability to detect and support multi-jurisdictional outbreaks, to flag anomalies for further investigation, and to identify long-term trends in enteric disease nationally. Key findings in 2014 include *S.* Enteritidis, *S.* Typhimurium, and *S.* Heidelberg remaining the top three most commonly reported *Salmonella* serovars. However, of note was a significant increase in *S.* Enteritidis from 2013 to 2014 with *S.* Enteritidis representing 43% of all *Salmonella* isolates reported in 2014 compared to 32% in 2013. In 2014 there was also a continued stable incidence rate of *E. coli* O157 since its major decline in 2011. Finally, in 2014, there was an observed ongoing increase in testing and reporting procedures for *E. coli* non-O157 reflecting, at least in part, greater awareness and knowledge of clinically significant *E. coli* serovars other than *E. coli* O157.

Going forward, it is expected NESP data will continue to be relied upon as a method to support the real-time detection and response to emerging and priority diseases, to provide early warning signals to support public health action, and to identify long-term trends and integrate with national and international efforts to monitor and limit the spread of enteric diseases.

Questions and correspondence may be forwarded via email to NML.Enterics@phac-aspc.gc.ca

Appendix 1. Comparison of national totals, incidence per 100,000 and proportion captured between the Canadian Notifiable Disease Surveillance System (CNDSS) and NESP for enteric, food and waterborne diseases, 2013

Enteric, Food and Waterborne Diseases	Notifia Sur	anadian able Disease veillance m (CNDSS) ¹	Su	onal Enteric Irveillance Iram (NESP)	% of CNDSS cases captured in NESP (NESP isolations /		
2013	N	Rate per 100,000	N	Rate per 100,000	CNDSS cases⁵)		
Botulism	5	0.01	-	-	N/A		
Campylobacteriosis ²	10232	29.13	1866	-	18.2		
Cholera	1	< 0.01	1	< 0.01	100.0		
Cryptosporidiosis ²	830	2.36	341	-	41.1		
Cyclosporiasis ^{2,3}	146	0.42	17	-	11.6		
Giardiasis ²	3788	10.79	779	-	20.6		
Hepatitis A	212	0.60	217	0.61	102.4		
Invasive Listeriosis	128	0.36	117	0.33	91.4		
Paralytic Shellfish Poisoning ⁴	0	0.00	-	-	N/A		
Salmonellosis	6171	17.57	6270	17.77	101.6		
Shigellosis	682	1.94	621	1.76	91.1		
Typhoid	124	0.35	133	0.38	107.3		
Verotoxigenic <i>Escherichia</i> coli Infection	631	1.80	647	1.83	102.5		

¹NU did not report on any of these diseases in 2013. The population of the territory has been removed for rate calculation.

²Campylobacter and parasites (Cryptosporidium, Cyclospora and Giardia) are not routinely reported to provincial or central reference laboratories and are greatly under-represented in NESP; therefore no rate was calculated for NESP.

³NB did not report on Cyclosporiasis in 2013. The population of these provinces have been removed for rate calculation.

⁴MB, NB, NT, ON, and SK did not report on Paralytic Shellfish Poisoning in 2013. The population of these provinces and territory have been removed for rate calculation.

⁵Cases reported through the CNDSS and laboratory-confirmed isolations through NESP have not been linked, this is the degree of concurrence represented as a percentage of NESP isolations compared to the case count reported by the CNDSS. Percentages greater than 100 likely reflect cases with more than one isolate.

Appendix 2. Species and serovar data reported to NESP by province and territory, 2014

territory, 2				•				•						
NESP 2014	BC	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
Campylobacter														
coli	52	16	14	5	24	43	2		6	1				163
concisus						1								1
curvus						1								1
fetus ssp fetus	3	1			8	32								44
jejuni	350	248	119	88	114	99	134		30	32				1214
jejuni/coli								97		3				100
lari	4	2	1		3	7	1		4					22
rectus						2								2
upsaliensis	24	6	3		12	12	1		2					60
urealyticus	1													1
Campylobacter sp	2		1				62	2		1				68
Total	436	273	138	93	161	197	200	99	42	37	0	0	0	1676
Campylobacter	436	2/3	130	93	101	197	200	99	42	31	U	U	U	10/0
Escherichia coli														
O5:H Nonmotile		2	1			1								4
O13:H Undetermined						1								1
O26:H11	8	8	8											24
O26:H Nonmotile	1	1	3			1								6
O41:H2	1													1
O43:H2	1													1
O49:NM			1											1
O52:H45					2	4								6
O75:H21	1													1
O77:H45	1													1
O80:H14			1											1
O96:-:-			1											1
O98:H Nonmotile					1									1
O103	1													1
O103:H2	2				2	1								5
O103:H21			1											1
0111				1										1
O111:H Nonmotile	12	5		1	1	1								20
O112ab:H Nonmotile	1													1
O117:H7	4													4
O118:H	1		1											2
Undetermined			'											
O121	1													1
O121:H1	1		1											2
O121:H9	1													1
O121:H19	6	2	6			1								15
O126:H8	1													1
O127:VT-				1										1
O128:- VT-				1										1
O128ab:H2						1								1
O145:H19			1											1
O145:H25						1								1
O145:H Nonmotile			1											1
O146:H Nonmotile						1								1

NEOD COAA		4.0	014		ON.		LND	NO	-		- V-1			T . (.)
NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
O156:H19			1											1
O157			4	20						1				25
O157:H7	51	178		2	102	48	3	7	9					400
O157:H16		1												1
O157:H Nonmotile	4	7			14	5		2						32
O172:H16			1											1
O182:H			1											1
Undetermined														
O182:H19			1											1
O186:H2	3		2											5
O186:H Nonmotile		1												1
O-Rough:H	2													2
Undetermined O-Rough:H1	1													1
O-Rough:H2	l l	1												1
	1	-												
O-Rough:H7	I					4								1
O-Rough:H16					4	1								1
O-Rough:H45					1	1			4					2
Inactive	4			4.4					1	_				1
Non-O157 VTEC	4			11		40				7				22
Non-Typed VTEC	14	222		3	100	16			4.0					33
Total E. coli	124	206	36	40	123	84	3	9	10	8	0	0	0	643
Listeria			_				_							
monocytogenes	18	10	2	3	45	46	3	4	1	1				133
Salmonella enterica s											1			
Aarhus	1													1
Aberdeen				1	3									4
Abony		1			1									2
Adelaide		1			1									2
Agona	15	15	2		33	10	2	1						78
Ajiobo	1													1
Alachua	1				1	1								3
Albany	4		1		4									9
Altona					3									3
Amager	1													1
Amsterdam			1		1									2
Anatum	5	4	1		14	2	1							27
Арара					1	2								3
Arechavaleta	1				7			1						9
Bardo					6									6
Bareilly	4	3	1	1	7									16
Benin					1									1
Berta					5				1					6
Bispebjerg	1													1
Blockley					2	1								3
Bonariensis	1	1			4									6
Bovismorbificans	6	3			13	12								34
Bradford		-			_	-								1
Diauloiu		1												
	6	10	2	2	22	25	1	2		1				
Braenderup	6	10	2	2 5	22	25 4	1	2		1				71
	6 4		2	2 5	22 4	25 4 1	1 1	2		1				

NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
Bredeney	1	1	OIX	IVID	2	Q.O	140	140		142	••	- 111	140	4
Carrau	1													1
Cerro	ı	1			1									2
Chailey		1			ı									1
	2	- 1	1		9	7								
Chester	2		1		9	7								19
Choleraesuis		4				2								2
Colindale	_	1	4		4.4	_								1
Corvallis	5	2	1	1	11	1								21
Cotham	2	1			4									7
Cubana	_				2									2
Daytona	6	_												6
Derby		2			16	10								28
Drogana					1									1
Dublin	3	2			5	9								19
Durban					1									1
Ealing		1												1
Eastbourne					13	6		2						21
Ebrie	3				2									5
Edinburg					2									2
Emek		1			2									3
Enteritidis	629	494	84	99	1225	507	100	128	21	48		1	1	3337
Fairfield					1									1
Florida						1								1
Fresno	1													1
Gaminara					1									1
Gatuni					1	1								2
Give	4	1			4	2	1							12
Goettingen			1		2									3
Goverdhan	2				1									3
Hadar	8	2	2	14	20	9	1	1		3		1		61
Haifa	1	2	1		3	1	-	-				-		8
Hannover			•		1	•								1
Hartford	6	5	1		31	2								45
Havana	1	0			4	2								7
Heidelberg	32	38	9	13	289	195	20	18		13			1	628
Herston	02	30	3	10	203	1	20	10		10			'	1
Holcomb					1									1
Hvittingfoss	1	1		1	9								1	13
Idikan	ı	ı		'	1								ı	1
Indiana					3	2								5
	25	10	4	11	74		2	4	-1	2				
Infantis	25	12	1	11		35	2	1	1	2				164
Inverness	4	4			1									1
Irumu	1	1			2									4
Isangi		4			2									2
Istanbul		1	_			. =	_							1
Javiana	24	16	4	7	56	19	2	3	2					133
Johannesburg					1	1								2
Kedougou		1			1									2
Kentucky	7	2			15	6								30
Kiambu	2	3	1	3	11	2								22

11505 0044			014		011			110			L > r=1			
NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
Kintambo					3	1								4
Kirkee					1									1
Kisarawe					1	_								1
Kottbus		1			1	2								4
Kouka					1									1
Lagos					2									2
Larochelle					1	3								4
Lattenkamp	1				1									2
Litchfield	2			5	13	5	1			1				27
Liverpool	2				1									3
Livingstone	1	1			2									4
Lomalinda		2			2									4
London	2				3	1								6
Manhattan	3	2		5	14	3								27
Mbandaka	4	5			11	3	1	1						25
Meleagridis	2													2
Miami		1			2	5								8
Michigan	1	1												2
Mikawasima					1									1
Minnesota	1	1	1			1								4
Mississippi		1	3	1	3	2		1						11
Monschaui	1					1								2
Montevideo	5	6	2	1	10	7								31
Muenchen	5	6	1	4	43	17	1	3		1				81
Muenster	1				2	3								6
Napoli	-	1			1	1								3
Nessziona						4		1						5
Newport	34	11	6	7	89	60	9	6	1	1				224
Norwich	0.1			,	1	1			•					2
Nottingham		1				'								1
Ohio		1		2		2								5
Okatie		•			1	1								2
Oranienburg	16	10	2	3	33	13	2	2						81
Ordonez	10	10		3	- 33	10								1
Orientalis	1													1
Oslo	4	3			3	1								11
Othmarschen	1	J			1	ı								2
Overschie					1									1
Oxford					'	1								1
Panama	0	•			40	1								
	2	6	4	2	19	4		4						31
Paratyphi A	19	10	1	2	27	4		1						64
Paratyphi B	4	40	_	2	1	1								8
Paratyphi B var. Java	15	12	3		18	8								56
Pensacola		1			•									1
Pomona		3		1	3	2								9
Poona	3	4			8	4	1			1				21
Potsdam	1	1												2
Praha					1									1
Putten					1									1
Reading	6	6	2		4							1		19

NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
Richmond	1	AD	JK.	IVID	2	y c	IAD	143		IVE		141	140	3
Rissen	4	1			4	1								10
Rubislaw	3	ı ı			2	_								5
Ruiru	3				2	1								1
Saintpaul	28	28		5	40	25	1	2	1	1				131
Sandiego	3	3	1	1	5	3			'					16
Schwarzengrund	9	7	6	1	25	9	1			1				59
	5	5	3	2	10	2	1	5	1	1				35
Senftenberg Seremban	3	5	3		10		1	5	'	ı				
	4				2	1								1 4
Singapore	1					1								
Solt	00	0		4	1	-		4						1
Stanley	28	6	3	4	27	3		1						72
Stanleyville						1								1
Takoradi					1									1
Tallahassee					1									1
Tarshyne		-			1									1
Telelkebir		2	1											3
Tennessee	2		1		6	1								10
Thompson	10	10		3	210	124	12	13	1	9				392
Tornow					1									1
Typhi	31	20	2	1	77	8		1						140
Typhimurium	77	94	15	19	307	134	10	8	3	3			1	671
Uganda	1	1		2	3	4	1	1						13
Urbana		1				2								3
Virchow	3	7			9	5	1	1						26
Wangata						1								1
Weltevreden	7	7		1	4	2								21
Worthington	1	1		1	1									4
species				6				1		3				10
ssp I	1			9				1	2					13
ssp I 1,3,19:-:-							1	1						2
ssp I 2,12:-:-					1									1
ssp I 3,15,34:l,z13,z28:1,7						1								1
ssp I 4,12:-:-						1								1
ssp I 4,[5],12,27:-:1,2		1				•								1
ssp I 4,[5],12:-:-		1			1									2
ssp I 4,[5],12:-:1,2		·				1								1
ssp I 4,[5],12:b:-		4			30	6								40
ssp I 4,[5],12:d:-	1	7			30	J								1
ssp I 4,[5],12:e,h:-	Į.					1								1
	36	48	16	3	96	43	7	2						251
ssp I 4,[5],12:i:-	30	40	10	3	90		,							
ssp I 4,[5],12:r:-		4				1								1
ssp 6,7,[14]:-:1,2		1												1
ssp 6,7,[14]:b:-		1												1
ssp 6,7,[14]:c:-		2												2
ssp I 6,7,[14]:k:-		2												2
ssp I 6,7:-:-					1									1
ssp I 6,7:c:-					1									1
ssp I 6,7:d:-	1													1
ssp I 6,7:e,h:-	1				1			1						3

NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
ssp I 6,7:k:-	1	AD		1110	1	40	140	140		IAF		141	140	2
ssp I 6,7:r:-					2									2
ssp I 6,7:y:-	1													1
ssp I 6,8:-:1,5	1													1
ssp I 6,8:d:-	1													1
ssp I 6,8:e,h:-	1				1									2
ssp I 6,8:r:-	_				'	2								2
ssp I 9,12:-:-					1	4								5
ssp I 9,12:-:1,5	1	5			3	1	1	3						14
ssp I 9,12:1,z28:-		3			2	!		3						2
ssp I 3,23:b:-					2		1							3
ssp I 13,23.b					1		- 1							1
					1									1
ssp I 16:I,v:-		4			ı	4								2
ssp I 50:y:-		1				1								
:l,z13,l,z28:e,n,z15						1								1
ssp I O19:d:-	1													1
ssp I O50:-:-						1								1
ssp I Rough-O:-:-	1	2			6	2								11
ssp I Rough-O:-:1,5						1								1
ssp I Rough-O:-:1,6						1								1
ssp I Rough-O:b:l,w						1								1
ssp I Rough-O:d:1,2		1			2									3
ssp I Rough-O:e,h:-					1									1
ssp I Rough-O:g,m:-		1					1							2
ssp I Rough-O:i:-					1									1
ssp I Rough-O:k:-						1								1
ssp I Rough-O:k:1,5					1									1
ssp I Rough-O:m,t:-			1											1
ssp I Rough-O:r:1,2	1													1
ssp I Rough-O:z10:-	2													2
ssp I Rough-					1									1
O:z4,z23:- ssp I Rough-O:z:-					1									1
	1				ı									1
ssp I Rough-O:z:l,w ssp II 4,12:g,m,t:-					1									1
ssp II 4,7:z4,z23:-		1			ı									1
ssp II 42:z29:-	1													1
ssp II 42:229:- ssp II 43:g,z62:e,n,x	_				1									1
					1									1
ssp II 47:b:1,5 ssp II 58:l,z13,z28:z6	1				1									•
					4									1
ssp IIIa 21:g,z51:-		3			1	1								1 5
ssp IIIa 41:z4,z23:-	1	3			ı	1								
ssp IIIa 47:z4,z23:-	1					1								1
ssp IIIa 53:z4,z23:-	4			4		1								1
ssp IIIb	1			1	_	_								2
ssp IIIb 16:z10:e,n,x,z15	1													1
ssp IIIb 38:k:1,5,7		1												1
ssp IIIb 47:k:z35					1									1
ssp IIIb 48:i:z:[z72]		1												1
		•			•	•	•	•					•	

NESP 2014	DC	AD	CK	MD	ON	00	ND	NC	DE	NII.	YT ¹	NT	NIII	Total
	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YI	NT	NU	Total
ssp IIIb 50:k:z					1									1
ssp IIIb 50:l,v:z35	4				1									1
ssp IIIb 50:r:z53	1													1
ssp IIIb 53:-:-					1									1
ssp IIIb 53:z10:z					1									1
ssp IIIb 53:z10:z35		1			1									2
ssp IIIb 60:r:e,n,x,z15	1													1
ssp IIIb 61:-:1,5,7						2								2
ssp IIIb 61:i:z							1							1
ssp IIIb		1												1
61:l,v:1,5,7:[z57]		4												
ssp IIIb 65:z52:z		1												1
ssp IIIb Rough-O:l,v:z					1									1
ssp IV						1								1
ssp IV 6,7:z4,z23:-					1									1
ssp IV 16:z4,z32:-					1									1
ssp IV 44:z4,z23:-	1													1
ssp IV 45:g,z51:-						1								1
ssp IV 48:g,z51:-	1													11
ssp IV 50:g,z51:-		2												2
ssp IV 50:z4,z32:-					1									11
Total Salmonella	1231	1008	184	250	3207	1443	185	213	34	89	0	3	4	7851
Shigella species			ı	ı		l	ı	ı			ı	ı		
boydii				2						1				3
boydii 1	1				1									2
boydii 2					3	1								4
boydii 4					3									3
boydii 8	1													1
boydii 10	2	1			2									5
boydii 11					1									1
boydii 12	1													1
boydii 14	2													2
boydii 19	2													2
boydii 20	1													1
dysenteriae 2	3				2									5
dysenteriae 4														2
dysenteriae 16					2									_
a, comemue 10	2				2									2
flexneri 1	2				2									
					2	1								2
flexneri 1		4			8	1 2		1						2 11
flexneri 1 flexneri 1a	11	4						1						2 11 1
flexneri 1 flexneri 1a flexneri 1b	11	4 8						1	1					2 11 1 16
flexneri 1 flexneri 1a flexneri 1b flexneri 2	11 1 13				8	2		1	1					2 11 1 16 13
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a	11 1 13				8	2		1	1					2 11 1 16 13 33
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b	11 1 13 1				8	2		1	1					2 11 1 16 13 33 4
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a	11 1 13 1	8			8 17 4	6		1 2	1					2 11 1 16 13 33 4 15 81
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a flexneri 3b	11 1 13 1 15 4	2			8 17 4 42 12	6 33			1					2 11 1 16 13 33 4 15 81 23
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a flexneri 3b flexneri 3c	11 1 13 1 15 4 3	2			8 17 4 42	6 33 5			1					2 11 1 16 13 33 4 15 81 23
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a flexneri 3b flexneri 3c flexneri 4	11 1 13 1 15 4	2 1			8 17 4 42 12 1	6 33			1					2 11 1 16 13 33 4 15 81 23 1
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a flexneri 3b flexneri 3c flexneri 4 flexneri 4a	11 1 13 1 15 4 3	2			8 17 4 42 12 1 5	6 33 5			1					2 11 1 16 13 33 4 15 81 23 1 3 7
flexneri 1 flexneri 1a flexneri 1b flexneri 2 flexneri 2a flexneri 2b flexneri 3 flexneri 3a flexneri 3b flexneri 3c flexneri 4	11 1 13 1 15 4 3	2 1			8 17 4 42 12 1	6 33 5			1					2 11 1 16 13 33 4 15 81 23 1

NESP 2014	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	YT ¹	NT	NU	Total
flexneri 6	7	4	3K	IVID	5	1	IAD	143	FE	INL	"	INI	NO	17 17
flexneri 6	/	4			5	1								17
Hertfordshire					2									2
flexneri			4	12		1	1							18
flexneri Prov. SH-104	5	1			4									10
flexneri var. X	6	1			2									9
flexneri var. Y		1			1	1		1						4
sonnei	50	63	11	18	157	68	3	3	2					375
Shigella sp	1													1
Total Shigella	136	88	15	32	275	120	4	7	3	1	0	0	0	681
Vibrio														
albensis						1								1
alginolyticus		1			1	3		1						6
cholerae		1												1
cholerae O1	1													1
cholerae O1 Ogawa						1								1
cholerae non-	2	4	4		2	_	_		4		1			4.4
O1/O139	2	1	1		2	5	1		1		1			14
fluvialis	2	2						1						5
furnissii						1								1
hollisae	1													1
parahaemolyticus	33	14			1		1	1						50
Vibrio sp						1								1
Total Vibrio	39	19	1	0	4	12	2	3	1	0	1	0	0	82
Yersinia species														
bercovieri						2								2
enterocolitica	63	39	18		124	50	4	1		2	1			302
frederiksenii	11	2	4			2								19
intermedia	1	6	3			4								14
kristensenii						1								1
pseudotuberculosis	3													3
Total Yersinia	78	47	25	0	124	59	4	1	0	2	1	0	0	341
Parasites			•			•			,	,	•	,	•	
Cryptosporidium	18	2	26	94	225	3	15	25	6	4	1			419
Cyclospora				5	22			1						28
Entamoeba	137		16	30	91	257	4	2			9			546
histolytica/dispar														
Giardia	59	4	79	75	293	100	83	86	9	20	10			818
Total Parasites	214	6	121	204	631	360	102	114	15	24	20	0	0	1811
Viruses	ı	ı	ı		1			1	T	T		T		ı
Adenovirus	9	5		24	58			2						98
Astrovirus		2												2
Enterovirus				17						3				20
Hepatitis A	21	27	17	8	83	46		3		3				208
Norovirus	353	229	146	53	638	488	40	105	75	52		1		2180
Rotavirus	10	8	25	17	133		131	39	10	52				425
Total Viruses	393	271	188	119	912	534	171	149	85	110	0	1	0	2933

¹ In the Yukon bacterial case counts (including *Campylobacter*, *E. coli*, *Salmonella* and *Shigella*) are frequently reported through British Columbia, and are therefore not representative of the province.

Appendix 3. Phage types of isolates submitted to the NML, 2014¹

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Escherichia coli												
E. coli O157:H7	1					1	1					2
	2	1	5		4	21	2		1	1		35
	4	1	2			11	3	1				18
	8	1	4			12	18					35
	14	3	17	1	1	9	5		1			37
	21					1						1
	24					1						1
	31		1				1					2
	32	1	3	1		2						7
	33					1						1
	34		1		1	3	1		1	1		8
	42					1						1
	49		1		1	5	1					8
	54					3			2			5
	70					1						1
	74		1			1	1					3
	77					1						1
	95				1							1
	14a	7	141	1	10	38	12	2	2	7		220
	14c					1						1
	14d					1						1
	32a	1		1		3	1					6
	ATEC-04						1					1
	ATEC-09					3						3
	ATEC-12					1						1
	ATEC-13					1						1
	ATEC-15		1									1
	ATEC-16					1						1
	ATEC-17					2						2
	ATEC-19					2						2
	ATEC-20					1						1
	Untypable						1					1
	Subtotal	15	177	4	18	128	48	3	7	9	0	409
E. coli O157:HNM	4					_	1		1			2
	8	1				7	3				1	12
	14								1			1
	31		1									1
	32						1					1
	33					1						1
	54					1						1
	70		•			1						1
	14a		6									6
	14c	1				2						3
	ATEC-18		-	•	•	1	-		_		_	1
	Subtotal	2	7	0	0	13	5	0	2	0	1	30

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Salmonella	· ilago i ypo		, , ,	O.C		0.1				· -		· otal
S. enterica ssp enterica (I) 4,[5],12:b:-	3b					1						1
	3b var 2					1						1
	ATPB-01					1						1
	ATPB-05					7	1					8
	ATPB-07					3	1					4
	ATPB-09					1						1
	Battersea					2	1					3
	Dundee					1	1					2
	Dundee var 1		1									1
	Stirling						1					1
	Untypable	2	4	1		2	1					10
	Subtotal	2	5	1	0	19	6	0	0	0	0	33
S. enterica ssp enterica (I) 4,[5],12:i:-	27						3					3
	35						4					4
	41					2	1					3
	51		1									1
	120	1				1	3					5
	151		1									1
	166					1						1
	178	1										1
	186	1				2						3
	191		1	4	3	6	3		1	1		19
	192					1						1
	193	12	17	5	4	39	17	1				95
	195					1						1
	104a						1					1
	104b		2			1						3
	191a		7	1			1		1			10
	193a					2						2
	ATTM-04	1	2	1							1	5
	ATTM-100			1								1
	ATTM-11		1									1
	ATTM-115		1									1
	ATTM-116		7	1		1						9
	ATTM-117					1						1
	ATTM-120			1				_				1 -
	ATTM-123							5				5
	ATTM-125			_		1						1
	ATTM-131			2								2
	ATTM-135	1				4						1
	ATTM-139					1						1
	ATTM-149					2						2
	ATTM-40					1						1
	ATTM-78				0	1						1
	ATTM-82				2	2	1					4

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Organioni	ATTM-86	50	AB	OIX.		2	40	145	110		.,,_	2
	ATTM-92					_	1					1
	ATTM-97						1					1
	ATTM-98		1				'					1
	ATTM-99		1			2						3
	U291	1	4		3	13	5					26
	U302		7		3	1	1					2
	U311		1				1	1				3
	Untypable					1	1	1				1
	UT1		1			2	1					4
	UT2		'			1	'					1
	UT6		1									1
	UT7					1						1
	Subtotal	18	49	16	12	89	43	7	2	1	1	238
S. enterica ssp enterica			7.5						_			
(I) O Rough:i:1,2	Untypable						1					1
	Subtotal	0	0	0	0	0	1	0	0	0	0	1
S. Enteritidis	1	24	12	6	4	88	42	1	6		1	184
	2	2	2	1	1	16	4					26
	3		1			3						4
	4	5	5			13	4					27
	6					2	1					3
	7	1										1
	8	197	146	27	36	441	160	47	59	10	32	1155
	13	161	44	5	5	175	69	13	17	4	4	497
	18	4	7			3						14
	19	1				1	2					4
	21	4	1	1	2	8	1				1	18
	22	2	4			15	5	1	1			28
	23	3	2			1	1					7
	26	1										1
	29		1									1
	31	1										1
	34		51				1	1			1	54
	35	36	44	9	6	64	26	6	4	1	5	201
	37								1			1
	38	2										2
	41	1										1
	43	1	1				2				1	5
	47						3					3
	51	7				7	3		1			18
	52					1						1
	53					1						1
	55						1					1
	56		1									1
	59			2		1						3
	63	8	4		1	37	15					65

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
	64	13	38	10	13	172	66	15	24	4	3	358
	11b					1						1
	13a	123	101	13	16	78	31	5	2			369
	14b	5				5	1					11
	14c						1					1
	15a					2	2					4
	1a					1	1					2
	1b	5		1		7	2	4			1	20
	21c	4	2			1	3					10
	29a						2					2
	4b	2	2			2	1		1			8
	5a						2					2
	5b	5	6	1	8	46	23	1	8	1		99
	6a	8	7	1	2	10	5					33
	7a	1			1							2
	9a					3	1					4
	9b	1					1					2
	ATEN-01					3	1					4
	ATEN-02	1				2	1		1			5
	ATEN-03		1									1
	ATEN-05	1					1					2
	ATEN-07	1										1
	ATEN-12					2	1					3
	ATEN-15	1				1						2
	ATEN-17	1										1
	ATEN-31					1						1
	ATEN-34					1			1			2
	ATEN-39					1						1
	ATEN-40		1						1			2
	ATEN-41					1						1
	ATEN-46	1										1
	ATEN-47		1									1
	ATEN-48	1										1
	ATEN-49	1				1						2
	ATEN-50	1	3	1		4						9
	ATEN-51		1		1	1						3
	ATEN-52					1						1
	ATEN-53					5	2		1			8
	ATEN-54							1				1
	ATEN-55	1					2					3
	ATEN-56		1									1
	ATEN-57				1	2						3
	ATEN-58	1										1
	ATEN-59					1						1
	ATEN-60									1		1
	ATEN-61					1						1
	ATEN-62					1						1

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Organism	Non-Viable	ВО	AD	OIX	2	1	QU	IND	140		IVE	3
	Untypable	3	1	3	1	2	8				1	19
	Subtotal	642	491	81	100	1237	498	95	128	21	50	3343
S. Hadar	2	<u> </u>		<u> </u>	100	6	3		1		1	11
0.11000	5	2			12				•		•	14
	10	_			1	1						2
	11	1						1			1	3
	18		1									1
	33				4							4
	47		2	1								3
	56	1				1						2
	ATHR-03					1						1
	Subtotal	4	3	1	17	9	3	1	1	0	2	41
S. Heidelberg	1					1						1
	2	1	1			2	4	1				9
	4						1					1
	5		1			11	3					15
	9		1		2	1						4
	10	1	1			22	5		2		1	32
	11	1			1							2
	17						3				1	4
	18	1	2			6	1					10
	19	10	12	7	5	109	63	6	4		9	225
	22	1				1	1					3
	24					6						6
	26		2			3	5		4			14
	29	10	10		1	57	58	3	3			142
	32		1	1	1	2	11	1			1	18
	37					1						1
	39				1	1	1					3
	40					1	2					3
	41	4	3			14	3		1			25
	44						1					1
	47						1	4			1	2
	51						4	1				5
	52					2	1					3
	53 54					1 2	4					5 3
	55					2	ı					2
	57					1						1
	58		2			3	4					9
	19a			1		10	4	5	3			23
	19b					10	4	J	J			1
	19b					1						1
	29a					1	3					4
		1			l	ı '		l		l	l	
	40a				1	3						4

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
3	ATHE-01					1						1
	ATHE-02					1						1
	ATHE-04					1						1
	ATHE-05					•		1				1
	ATHE-06					1		•				1
	ATHE-08					1		1				2
	ATHE-16					•	1	•				1
	ATHE-18					2	-					2
	ATHE-21					1	1					2
	ATHE-23						1					1
	ATHE-24					1						1
	ATHE-25						1					1
	ATHE-26					1						1
	ATHE-28	5										5
	ATHE-29					1						1
	ATHE-30					1						1
	ATHE-31						1					1
	ATHE-32						2					2
	ATHE-34					1						1
	ATHE-35						1					1
	ATHE-36					1						1
	ATHE-37		1									1
	ATHE-38					1						1
	ATHE-39								1			1
	Non-viable					1						1
	Subtotal	34	37	9	12	282	193	19	18	0	13	617
S. Infantis	1		1		1	1						3
	3		1		2	2	2					7
	4	1	2		1	15	5				1	25
	6	1				2				1		4
	7	5	7			22	5	2			1	42
	8	2			1		1					4
	9					2			1			3
	12					1						1
	13	1				4	2					7
	24						1					1
	26					1	1					2
	Untypable		1		5							6
	Subtotal	10	12	0	10	50	17	2	1	1	2	105
S. Newport	1					3	1					4
	2	2				2	5	2				11
	3			1		_	3	1				5
	4					2						2
	5	1	1				1					3
	6					1	_					1
	9	1	3		3	15	8	2	1		1	34
	10	3				2	18	1				24

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
o.gamom	11		713	0.1	2	0.1	3					3
	13	1	1			10	3	2		1		18
	14	•	•			2	2	_		•		4
	15					4	1		1			6
	16				1	1	•	1	•			3
	14a	1			1	1	1	•				4
	14b	2	2	1	•	7	2					14
	17a	_	1			2	_		1			4
	1a	1	•			1			•			2
	ATNP-01	•				1	3					4
	ATNP-02	1	1	1		2						5
	ATNP-05	•	•	•		1						1
	ATNP-06						1					1
	ATNP-07	4	1			10	4					19
	ATNP-11	'	'			1	'					1
	ATNP-14	1										1
	ATNP-18	1				2			1			4
	ATNP-19					_	1					1
	ATNP-20			1			•					1
	ATNP-21	1		•		2						3
	ATNP-22	-			1	2	1					4
	ATNP-23				•	5	•		1			6
	ATNP-24			1		2			-			3
	ATNP-25			-		1						1
	ATNP-26					1						1
	ATNP-27					1						1
	Subtotal	20	10	5	6	84	58	9	5	1	1	199
S. Oranienburg	1			1	1	8	6				1	17
	2		1									1
	6	3			1	4	3	2				13
	8	2	3	1		1	2					9
	11		1			1			1			3
	12		1				1					2
	15		1		1	3						5
	ATOR-01	4										4
	ATOR-06		2									2
	ATOR-10					2						2
	ATOR-12		1									1
	ATOR-13		1									1
	ATOR-14	1										1
	ATOR-15					1						1
	ATOR-16								1			1
	ATOR-17					1	1					2
	ATOR-18						1					1
	ATOR-19					1						1
	Subtotal	10	11	2	3	22	14	2	2	0	1	67
S. Panama	Α	1	2			4						7

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Organism	ATPA-04	ВС	AB	3K	IVID	1	QC	IAD	INO	PE	INL	10141
	ATPA-04											
	ATPA-05		1			1						1
	G		1			1						2
	Н	1	1			1	4					
		1	4			4	1					2
	Untypable	2	1	•	•	1	4	•	^	^	^	
C. Douatumbi D	Subtotal	2	5	0	0	8	1	0	0	0	0	16
S. Paratyphi B	ATPB-01	2			4							2
	ATPB-07	1			1		4					2
	ATPB-08						1					1
	ATPB-10					4	1					1
	Battersea		4			1						1
	Sterling		1									1
	Worksop		1	_	2		_	_	_	_	_	2
C Danet	Subtotal	3	2	0	2	1	2	0	0	0	0	10
S. Paratyphi B var. Java	1 var 2					2						2
	1 var 6					1						1
	3b var 7	1					4					1
	ATPB-03	_	_				1					1
	ATPB-07	4	2	1		1	3					11
	ATPB-11					1						1
	ATPB-12					1						1
	ATPB-13		_			1	_					1
	Battersea		3	1		1	2					7
	Untypable						1					1
	Worksop		2	-	-	-		-	_	_		2
	Subtotal	5	7	2	0	8	7	0	0	0	0	29
S. Thompson	1	2	6		2	159	71	11	9	1	8	269
	2					7	3					10
	3					1						1
	5						1					1
	14					2		1	2			5
	25					4	2					6
	26					1						1
	ATTH-02					3						3
	ATTH-03					2			1			3
	ATTH-04		2			6	3					11
	ATTH-05					7						7
	ATTH-09		1		1	1						3
	ATTH-10		1			1						2
	ATTH-11	1					1					2
	ATTH-12					1						1
	Untypable						1					1
	Subtotal	3	10	0	3	195	82	12	12	1	8	326
S. Typhi	28					4						4
	35	1				2						3
	53						2					2

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
	A	2	5	-		2						9
	D2				1							1
	DVS	1	3			2						6
	E1	17	3			29	2					51
	E2					1						1
	E9 var	2	2			9	1					14
	E9var					1						1
	J1		1			1						2
	M1						1					1
	Non-viable	1										1
	Т					2						2
	Untypable	6	2	1		12			1			22
	UVS	6	4			8						18
	UVS I+IV	8		1		6	1					16
	Subtotal	44	20	2	1	79	7	0	1	0	0	154
S. Typhimurium	1	5	3		1	8	1					18
	2	1	2		1	6	2	1	1			14
	3		1									1
	8		1			5				1		7
	9	_	_		1							1
	10	3	2		5	37	6				1	54
	11		1				_					1
	12	3	1		1	13	5					23
	21					1	2					3
	22 35		1			1 2	1					2 5
	39		1			2	2					2
	40		1				2					2
	41	1	4	1	1	8	1		1			17
	46	!	4	1	1	2	1		1			2
	66		2			4	2					8
	69					4	1					5
	75	1				•	'					1
	93	1							1			2
	99		4			1	1	1				7
	104	8	37	9	2	14	8	1	2			81
	105					1						1
	107					1						1
	108	2	4		2	45	3		1	1		58
	110					1						1
	116	1				1						2
	120	2	2		1	1	2	2				10
	125					1						1
	132		1				6					7
	135	1	1			4	2					8
	136					2						2
	137		1									1

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
	141					1						1
	160	1					1					2
	161					1						1
	170					1						1
	177						1					1
	179		1			1						2
	186						2					2
	191					1	2					3
	193	3	7		1	9	13				1	34
	195		1	1		2	2					6
	208					1	3					4
	104a					5	7					12
	104b			1	3	23	15				1	43
	110b					1	2					3
	15a	3	1									4
	179 var		1				2					3
	193a	1				1	1					3
	2a				1							1
	46a						1					1
	66a						1					1
	ATTM-04					1						1
	ATTM-101							1				1
	ATTM-102									1		1
	ATTM-103					1						1
	ATTM-104		1			1						2
	ATTM-106					1						1
	ATTM-107							1				1
	ATTM-108		1									1
	ATTM-109	1	1			5	2		2			11
	ATTM-110					1						1
	ATTM-111					3						3
	ATTM-112					1						1
	ATTM-113					1						1
	ATTM-114		1									1
	ATTM-118					1						1
	ATTM-119					1						1
	ATTM-12		1			4						5
	ATTM-121				1							1
	ATTM-122						1					1
	ATTM-124						1					1
	ATTM-126					1						1
	ATTM-127					1	1					2
	ATTM-128				1	1						2
	ATTM-129					1						1
	ATTM-13					1						1
	ATTM-130					1						1
	ATTM-132					1						1

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
	ATTM-133	1										1
	ATTM-134					1						1
	ATTM-136					1						1
	ATTM-137					1						1
	ATTM-138	1										1
	ATTM-140					3						3
	ATTM-141					7	1					8
	ATTM-142					3						3
	ATTM-143					1						1
	ATTM-144					1						1
	ATTM-145						1					1
	ATTM-146					2						2
	ATTM-147						2					2
	ATTM-148					1						1
	ATTM-15						1					1
	ATTM-150					1						1
	ATTM-151						1					1
	ATTM-152					1	•					1
	ATTM-154					1						1
	ATTM-155					1						1
	ATTM-156	1				•	1					2
	ATTM-16	•				1						1
	ATTM-20					1						1
	ATTM-22					•	1					1
	ATTM-24				1							1
	ATTM-66				•	1						1
	ATTM-78					1						1
	ATTM-82					2						2
	ATTM-83				1	_						1
	ATTM-84	1			•							1
	ATTM-85	1										1
	ATTM-87					1						1
	ATTM-88					2						2
	ATTM-89		1									1
	ATTM-90					1						1
	ATTM-91					1						1
	ATTM-93					1						1
	ATTM-94					1						1
	ATTM-95	1										1
	ATTM-96	1					1					2
	U284						1					1
	U291					1						1
	U297		1			•						1
	U302	1	1			13	12	1				28
	U303	'	'			.0	1	'				1
	U310				1		1					2
	U312					1	1					2

Organism	Phogo Typo	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
Organism	Phage Type			3N	IVID			ND	INO	PE	NL	
	Untypable	1	4			5	1					11
	UT 5	1	1	4		5	4					1
		1		1			1					8
	UT2					1						1
	UT4		4	4		1						1
	UT5		4	1		4						5
	UT6					1						1
	UT7	40	0.7	44	0.5	1	400	0	•	•	•	1
Ohimalla	Subtotal	48	97	14	25	305	133	8	8	3	3	644
Shigella						1						4
Shigella boydii 1	9 Subtotal	0	•	0	_	1		_	0	0	_	1
Chinalla havdii 40		U	0	U	0	1	0	0	U	U	0	1
Shigella boydii 10	15		1			1						1
	ATSB-04	_	A	^	^	1	^	^	0	_	0	1
Chigolle houd!: 44	Subtotal 18	0	1	0	0	1	0	0	U	0	U	2
Shigella boydii 11	Subtotal	0	0	0	0	1	0	0	0	0	0	1 1
Shigella boydii 18	12	U	U	U	1	1	U	U	U	U	U	1
Snigelia boyali 16	Subtotal	0	0	0	1	0	0	0	0	0	0	1
Chigalla haydii 10		0	U	U	1	U	U	U	U	U	U	
Shigella boydii 19	12	1										1
	3	1				1						1
	Subtotal	1	•	^	^	1	•	^	0	^	_	2
Chinalla havdii 0		3	0	0	0	1	0	0	U	0	0	4
Shigella boydii 2	13					1						1
	6 ATSB-03					1						1
	Subtotal	0	0	0	0	3	0	0	0	0	0	3
Chigalla haydii 20	3		U	U	U	3	U	U	U	U	U	
Shigella boydii 20	Subtotal	1 1	0	0	0	0	0	0	0	0	0	1 1
Shigella boydii 4	13	'	U	U	U	3	U	U	U	U	U	3
Shigelia boyuli 4	ATSB-01											
	Subtotal	0	0	0	0	4	0	0	0	0	0	4
Shigella sonnei	1	U	38	5	1	111	1	2	3	1	U	162
onigena sonner	2		2	J	1	1			3			3
	4		1	1								2
	7		2	1		4						6
	9					5						5
	10					3			1			1
	11					1			'			1
	15		2			2						4
	19					1						1
	19 1a			1		1						2
	ATSS-03			'		2						2
	ATSS-03					1						1
	ATSS-10					2						2
	ATSS-11			1								1
	ATSS-12			1		5				1		6
	A155-13					5						0

52 | NATIONAL ENTERIC SURVEILLANCE PROGRAM (NESP) 2014

Organism	Phage Type	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
	ATSS-14			1								1
	ATSS-15					3						3
	ATSS-16					1						1
	ATSS-17		1			2						3
	ATSS-18					1						1
	ATSS-19					1						1
	ATSS-20		1									1
	ATSS-21		15	1		3						19
	ATSS-22		1	1								2
	ATSS-23		1									1
	ATSS-24					2						2
	ATSS-25					1						1
	Subtotal	0	64	11	1	150	1	2	4	2	0	235
Total		866	1008	148	211	2690	1119	160	191	39	82	6514

¹These values include isolates submitted to the NML for research purposes and may also include a small number of strains that represent multiple isolates from the same patient.

Appendix 4. Non-O157 serovars of verotoxigenic *E. coli* tested by the NML, 2014¹

Serovar	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
O1:H Nonmotile									1		1
O1:H Undetermined					1						1
O2:H Nonmotile						2			1		3
O2:H6				1							1
O2:H40						1					1
O4:H1						1					1
O5:H Nonmotile		2	1			1					4
O6:H Nonmotile					1						1
O8:H Undetermined			1								1
O8:H10			1								1
O8:H19			3		1						4
O9:H Undetermined			1								1
O9:H10			1								1
O11:H Nonmotile			1								1
O11:H21			1								1
O13:H Undetermined						1					1
O15:H12			1								1
O15:H45							1				1
O18ac:H1									1		1
O18ac:H7									1		1
O18ac:H31					2						2
O21:H Nonmotile		1									1
O21:H25						1					1
O25:H Undetermined					1						1
O25:H1									1		1
O25:H4	1	1			1	1					4
O26:H Nonmotile	1	2	3	1		1				1	9
O26:H11	9	8	8	4						2	31
O28ab:H Nonmotile					1						1
O28ac:H Nonmotile					2						2
O28ac:H21			2								2
O29:H Nonmotile									1		1
O33:H Undetermined									1		1
O37:H10			1								1
O38:H21			1								1
O41:H2	3										3
O43:H2	1										1
O45:H12			1								1
O48:H23					1						1
O49:H Nonmotile			1								1
O52:H45					2	4					6
O62:H17			1								1
O69:H Nonmotile										1	1
O71:H Nonmotile					1						1

Serovar	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
O71:H8	В	AD	OIX	IVID	OIL	Q.O	IND	110		1	1
O73:H1			1							'	1
O74:H Nonmotile		1	1								1
O75:H21	1										1
O77:H45	1										1
O80:H14			1								1
O81:H Nonmotile			1		1	1					2
O81:H14				1	ı						1
	1			1							
O84:H Nonmotile	1				4						1
O86:H18			4		1						1
091:H10			1								1
O96:H Nonmotile			1		4						1
O98:H Nonmotile					1				4		1
O99:H6	_								1		1
O103:H2	2			1	2	1					6
O103:H21			1								1
O105:H8			1								1
O107:H Undetermined						1					1
O110:H Nonmotile			2								2
O110:H19			1								1
O111:H Nonmotile	13	5		3	1	1					23
O111:H8				1							1
O112ab:H Nonmotile	1										1
O112ab:H2	1										1
O117:H Nonmotile			1								1
O117:H2						1					1
O117:H7	6										6
O117:H32			1								1
O118:H Undetermined	1										1
O118:H16	1										1
O121:H1	2		1								3
O121:H19	8	3	7	3		1		1		2	25
O124:H Nonmotile					4						4
O126:H8	1										1
O128ab:H2						1					1
O132:H34					1						1
O134:H1			1								1
O136:H Nonmotile					1						1
O141ac:H10					1						1
O145:H Nonmotile		1	1	1							3
O145:H19			1								1
O145:H25						1					1
O146:H Nonmotile						1					1
O153:H2							1				1
O156:H19			1								1
O156:H7			1								1
O164:H Nonmotile					1						1

Serovar	ВС	AB	SK	MB	ON	QC	NB	NS	PE	NL	Total
O165:H4			1								1
O166:H15					1						1
O168:H21			1								1
O171:H16			1								1
O172:H Nonmotile	1										1
O172:H16			1								1
O174:H Undetermined	1										1
O174:H16			1								1
O174:H19			1								1
O175:H28		1									1
O179:H8			1								1
O181:H Undetermined	1										1
O181:H16	1										1
O181:H4			2								2
O182:H Undetermined			1								1
O182:H19			1								1
O183:H19			1								1
O184:H12			1								1
O186:H Nonmotile		1									1
O186:H2	3		2								5
O Rough:H 7	1										1
O Rough:H Nonmotile		1			2	2			2		7
O Rough:H Undetermined	2		1		1						4
O Rough:H1	1						1		2		4
O Rough:H10			1						1		2
O Rough:H12			1								1
O Rough:H15						1					1
O Rough:H16						1					1
O Rough:H19			1								1
O Rough:H2		1									1
O Rough:H45					1	1					2
O Rough:H8			2								2
O Untypable:H 34					1						1
Total E.coli	65	28	74	16	34	27	3	1	13	7	268

¹Inclusive of only those isolates where both serovar and toxin testing data were available. These data are not representative of national incidence, as not all human clinical shiga toxin-producing *E. coli* are sent to the NML for these reference service tests.